Press releases
-
April
17
ADVITECH OBTAINS SHAREHOLDERS APPROVAL OF THE PRIVATE PLACEMENT WITH AGECHEM AND PROCEEDS WITH THE CONVERSION OF DEBENTURES
TSX VENTURE EXCHANGE: AVI For immediate release
This news release is intended for distribution in Canada only and is not intended for distribution to United States newswire services or dissemination in the United States.
-
March
20
ADVITECH REPORTS THE FOURTH QUARTER AND YEAR-END RESULTS OF 2008
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - March 20, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces today its financial results for the fourth quarter of 2008 and for the year ended on December 31, 2008.
-
March
12
ADVITECH ANNOUNCES THE COMPLETION OF A CONDITIONAL PRIVATE PLACEMENT OF $1,000,000
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY - March 12, 2009 - Advitech Inc. (the "Corporation") (TSX-V : AVI), announced today that, further to the execution of the term sheet with AgeChem Venture Fund L.P. ("AgeChem") previously announced on February 10, 2009, it executed a binding conditional subscription agreement with AgeChem for the private placement (the "Private Placement") of 50,000,000 units at a price of $0.02 per unit.
-
February
10
ADVITECH EXECUTES A BINDING TERM SHEET FOR A $1M PRIVATE OFFERING
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - February 10, 2009 - Advitech Inc. ("Advitech" or the "Corporation") (TSX Venture Exchange: AVI) announces the execution of a binding term sheet for a $1 million private offering and changes to its management team.
-
November
28
ADVITECH REPORTS THIRD QUARTER 2008 FINANCIAL RESULTS
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
QUEBEC CITY, QUEBEC - November 28, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) today announced the financial results for the third quarter ended September 30 2008.
-
November
19
WOUND HEALING: ADVITECH ANNOUNCES AN AGREEMENT WITH URGO LABORATORIES
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
QUEBEC CITY, QUEBEC - November 19, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today that it has signed an exclusive collaboration agreement with Laboratories Urgo, one of the European leaders in the wound healing market.
-
October
22
ADVITECH SIGNS PL THOMAS FOR THE U.S. MARKET
TSX VENTURE EXCHANGE: AVI FOR IMMEDIATE RELEASE
QUEBEC CITY, QUEBEC - October 22, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today a distribution agreement with PL Thomas & Co., Inc. ("PLT") for the sale and marketing of its ingredient XP-828L for the United States market.
-
September
30
ADVITECH TO PRESENT AT BIOCONTACT CONFERENCE IN QUEBEC CITY
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - September 30th, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) a life sciences and technology company developing evidence based natural health products, today announced that Dr. Charles Doillon MD, PhD. will be presenting a progress report on the company's IM technological platform for wound management. The Advitech presentation is scheduled to begin at 15:00 p.m. local time on Wednesday, October 1st in the Bellevue room at the Chateau Frontenac Hotel in Quebec City.
-
August
26
ADVITECH ANNOUNCES HIGHLIGHTS AND RESULTS FOR THE SECOND QUARTER
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - August 26, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today highlights and financial results of its second quarter ended June 30, 2008.
-
July
31
ADVITECH ANNOUNCES STOCK OPTIONS GRANT
TSX VENTURE EXCHANGE: AVI For immediate release
QUEBEC CITY, QUEBEC - July 31, 2008 - Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces that pursuant to the Company's stock option plan, it has granted a total of 100,000 stock options to Luc Clouâtre, Vice-President Business Development, Sales and Marketing of Advitech. These options have an exercise price of $0.15 per share and may be exercised during a period of five (5) years. This grant of options is subject to appropriate regulatory approvals.
1 2 3 4